ODTX

Odyssey Therapeutics Inc

Jun 17 • 04:00PM ET

18.48

+0.61 3.41 %

Healthcare • Biotechnology • USA • Small • NASD

Today, 4:50 PMOdyssey Therapeutics reports positive Phase 2a OD-001 ulcerative colitis data, sees $464M cash funding operations into 2H 2028

Peers: ARVN BBOT XNCR CGEM CTMX JANX KURA ALLO RVMD ROIV

| Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	40.70%	Shs Outstand	47.17M	Perf Week	14.07%
Market Cap	871.78M	Forward P/E	-	EPS next Y	-4.02	Insider Trans	27.85%	Shs Float	27.97M	Perf Month	6.27%
Enterprise Value	-	PEG	-	EPS next Q	-0.87	Inst Own	9.70%	Short Float	1.84%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	26.67%	Inst Trans	13.76%	Short Ratio	1.20	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-6.32%	ROA	-	Short Interest	0.51M	Perf YTD	12.55%
Book/sh	-	P/C	-	EPS next 5Y	7.12%	ROE	-	52W High	20.30 -8.97%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	-6.04% -	ROIC	-	52W Low	15.35 20.39%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.14% 7.83%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	63.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	7.44%	Beta	-	Target Price	32.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	7.13%	Rel Volume	1.10	Prev Close	17.87
Employees	-	LT Debt/Eq	-	Earnings	Jun 03	SMA200	7.13%	Avg Volume	430.17K	Price	18.48
IPO	May 08, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	471,192	Change	3.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-26	Initiated	Wedbush	Outperform	$30
Jun-02-26	Initiated	TD Cowen	Buy
Jun-02-26	Initiated	Oppenheimer	Outperform	$40
Jun-02-26	Initiated	JP Morgan	Overweight	$26
Jun-02-26	Initiated	Cantor Fitzgerald	Overweight

Today 04:51PM	Odyssey Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:15PM	Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 08:31AM	Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip (GuruFocus.com) +6.27%

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

FounderDr. Gary D. Glick Ph.D.

Chief Financial OfficerMr. Jason Haas M.B.A.

Senior Vice President of Strategy & Business DevelopmentMr. Collin Todd

Ph.D.Prof. Eicke Latz M.D.

Scientific Co-FounderDr. Kim Lewis Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	Former 10% Owner	May 11 '26	Buy	18.00	1,388,889	25,000,002	3,690,146	May 13 05:10 PM
Dimension Capital II, L.P.	Director	May 08 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 12 05:37 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Buy	18.00	555,555	9,999,990	1,831,383	May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Sale	18.00	1,780	32,040	440,981	May 11 09:11 PM
LEIDEN JEFFREY M	Director	May 08 '26	Buy	20.00	5,000	100,000	270,198	May 11 08:35 PM
Haas Jason	Chief Financial Officer	May 08 '26	Buy	20.00	1,000	20,000	62,908	May 11 08:32 PM
Li Nan (LN)	Director	May 11 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 11 08:30 PM
Chu Shelley	Director	May 11 '26	Buy	18.00	11,111	199,998	11,111	May 11 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ODTX

Odyssey Therapeutics Inc

Upgrade your Finviz experience